依达拉奉联合血栓通对急性缺血性脑血管病病人Hcy及hs-CRP的影响  

Effects of Edaravone Injection and Xueshuantong Injection on the Homocysteine and hs-CRP in Acute Ischemic Cerebrovascular Disease

作　　者：黄艳君[1] 邹欣 孙函林 张中念[1] 董明[1] 肖黎黎 刘倩 舒鑫 王丽波 Huang Yanjun;Zou Xin;Sun Hanlin;Zhang Zhongnian;Dong Ming;Xiao Lili;Liu Qian;Shu Xin;Wang Libo(The Third Hospital of Mianyan/Sichuan Mental Health Center,Mianyang 621000,Sichuan,China)

机构地区：[1]四川省绵阳市第三人民医院/四川省精神卫生中心,四川绵阳621000

出　　处：《中西医结合心脑血管病杂志》2018年第17期2558-2562,共5页Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease

摘　　要：目的探讨依达拉奉联合血栓通对急性缺血性脑血管病病人同型半胱氨酸(Hcy)及超敏C-反应蛋白(hs-CRP)的影响。方法选取四川省绵阳市第三人民医院已确诊为急性缺血性脑血管病的病人132例作为研究对象。随机分为对照组(A组)、依达拉奉治疗组(B组)、血栓通治疗组(C组)及依达拉奉联合血栓通治疗组(D组),各33例。A组脱落3例,B组和C组均脱落2例,D组脱落1例。A组进行抗凝、降低颅内压、稳定血压和血脂、改善微循环等综合治疗,B组在A组的基础上使用依达拉奉,C组在A组的基础上使用血栓通,D组在A组的基础上使用依达拉奉联合血栓通治疗。分别于入院前、治疗1个疗程后运用美国国立卫生研究院卒中量表(NIHSS)、日常生活活动能力(ADL)及卒中病人运动功能评估量表(MAS)评分对病人神经功能和日常生活能力进行评估,并检测两组治疗前后Hcy及hs-CRP水平。结果D组总有效率为90.63%,分别高于A组、B组及C组的60.00%、80.65%、77.42%,差异有统计学意义(P <0.05);治疗后D组NIHSS评分低于A组、B组及C组(P <0.05),ADL评分、MAS评分均高于A组、B组及C组(P <0.05);治疗后D组血清Hcy及hs-CRP均低于A组、B组及C组(P <0.05)。结论依达拉奉联合血栓通可一定程度提高急性缺血性脑血管病的临床治疗效果,并降低血清Hcy及hs-CRP水平,通过减轻炎症反应及改善血液流变学指标,进而促进急性缺血性脑血管病病人神经功能恢复。Objective To investigate the effects of edaravone injection and Xueshuantong injection （XSTI） on homocysteine （Hcy） andhigh sensitivity C reactive protein （hs CRP） in patients with acute ischemic cerebrovascular disease （AICD）.Methods One hun -dred and thirty two patients with AICD were randomly divided into control group （group A, n =33）,and edaravone injection group（group B, n =33）,XSTI group （group C, n =33） and edaravone injection plus XSTI group （group D, n =33）.The defluxion cases were 3cases in group A,2 cases in group B,2 cases in group C,and 1 case in group D.Patients in group A were treated with routine treatment（anticoagulation, reduced intracranial pressure, stable blood pressure and blood lipids, and improved microcirculation）.Patients weretreated with edaravone injection in group B,XSTI in group C,edaravone injection plus XSTI in group D on the basis of routine treat -ment.The neurological function and ability of daily life were evaluated by the National Institutes of Health Stroke Scale （NIHSS）,activi-ties of daily living （ADL）,and Motor Assessment Scale （MAS） before admission and after one course of treatment,respectively.The lev -els of serum Hcy and hs CRP were measured before and after treatment.Results The total effective rate of group D was 90.63%,which was higher than of group A,group B,and group C（60.00%,80.65% and 77.42%）,respectively,and the difference was statisticallysignificant （P 〈0.05）.After treatment,the NIHSS scores in group D were lower than those in group A,group B,and group C （P 〈0.05）.The scores of ADL and MAS in group D were higher than those in group A,group B,and group C （P 〈0.05）.After treatment,serum Hcyand hs CRP levels in group D were lower than those in group A,group B,and group C （P 〈0.05）.Conclusion Edaravone injectionplus XSTI improve the clinical therapeutic effect,reduce serum Hcy and hs CRP levels,reduce inflammation,and improve blood rheol-ogy,and promote neurological recovery in patients

关 键 词：急性缺血性脑血管病 依达拉奉 血栓通 同型半胱氨酸 超敏C-反应蛋白 

分 类 号：R741[医药卫生—神经病学与精神病学] R289.5[医药卫生—临床医学]